A carregar...
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
Chronic myeloid leukemia (CML) is the consequence of a single balanced translocation that produces the BCR-ABL fusion oncogene which is detectable in over 90% of patients at presentation. The BCR-ABL inhibitor imatinib mesylate (IM) has improved survival in all phases of CML and is the standard of c...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2769239/ https://ncbi.nlm.nih.gov/pubmed/19920925 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|